{"nctId":"NCT02396316","briefTitle":"Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients","startDateStruct":{"date":"2015-04-02","type":"ACTUAL"},"conditions":["Glaucoma, Neovascular"],"count":54,"armGroups":[{"label":"Aflibercept","type":"EXPERIMENTAL","interventionNames":["Drug: Aflibercept (Eylea, BAY 86-5321)"]},{"label":"Sham Injection","type":"SHAM_COMPARATOR","interventionNames":["Drug: Sham Injection"]}],"interventions":[{"name":"Aflibercept (Eylea, BAY 86-5321)","otherNames":[]},{"name":"Sham Injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese men and women aged 20 years or older,\n* Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the anterior segment (both iris and anterior chamber angle),\n* Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization.\n\nExclusion Criteria:\n\n* Patients with angle-closure due to conditions other than Neovascular glaucoma\n* Patients with a known or suspected ocular or peri-ocular infection,\n* Patients with severe intraocular inflammation in the study eye,\n* Women who are pregnant, suspected of being pregnant or lactating,\n* Patients with known allergy to aflibercept.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1","description":"It compared the change in IOP from baseline to pre-dose at Week 1 between the aflibercept group vs the sham group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"8.7"},{"groupId":"OG001","value":"-4.9","spread":"10.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1","description":"NVI were assessed in the study eye using the NVI grading systems (grade 0 to grade 4). A subject who shows the improvement by at least one grade is considered to be improved. Percentage of subjects who had improved NVI grade was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":27},"commonTop":["Punctate keratitis","Injection site pain","Conjunctival haemorrhage","Eye pain","Headache"]}}}